OR Oncology Reports 1021-335X 1791-2431 D.A. Spandidos 10.3892/or.2018.6197 or-39-03-0929 Articles Meta-analysis of mRNA expression profiles to identify differentially expressed genes in lung adenocarcinoma tissue from smokers and non-smokers HeXiaona 1 * ZhangCheng 2 * ShiChao 2 LuQuqin 1 Department of Biostatistics and Epidemiology, School of Public Health, Nanchang University, Nanchang, Jiangxi 330006, P.R. China Center for Experimental Medicine, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China Correspondence to: Dr Quqin Lu, Department of Biostatistics and Epidemiology, School of Public Health, Nanchang University, 460 Bayi Avenue, Donghu, Nanchang, Jiangxi 330006, P.R. China, E-mail: quqinlu@ncu.edu.cn

Contributed equally

 032018 08012018 39 3 929 938 26062017 29122017 Copyright: © He et al. 2018 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Compared to other types of lung cancer, lung adenocarcinoma patients with a history of smoking have a poor prognosis during the treatment of lung cancer. How lung adenocarcinoma-related genes are differentially expressed between smoker and non-smoker patients has yet to be fully elucidated. We performed a meta-analysis of four publicly available microarray datasets related to lung adenocarcinoma tissue in patients with a history of smoking using R statistical software. The top 50 differentially expressed genes (DEGs) in smoking vs. non-smoking patients are shown using heat maps. Additionally, we conducted KEGG and GO analyses. In addition, we performed a PPI network analysis for 8 genes that were selected during a previous analysis. We identified a total of 2,932 DEGs (1,806 upregulated, 1,126 downregulated) and five genes (CDC45, CDC20, ANAPC7, CDC6, ESPL1) that may link lung adenocarcinoma to smoking history. Our study may provide new insights into the complex mechanisms of lung adenocarcinoma in smoking patients, and our novel gene expression signatures will be useful for future clinical studies.

 meta-analysis microarray differentially expressed genes lung adenocarcinoma smoking Introduction

Lung cancer is one of the most common types of cancer and is the leading cause of cancer-related mortality wordwide. Small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) are the most common types of lung cancer, of which NSCLC accounts for approximately 85% of all cases (1). Lung adenocarcinoma is the most common subtype of NSCLC (40%) in many countries (2,3). To date, many genetic factors have been proposed to be involved in lung adenocarcinoma, including several tumour-suppressor genes (TP53, CDKN2A, STK11, NF1, ATM, RB1, and APC) (4,5). Several new targeted therapies have resulted in considerable clinical benefits for cancer patients in recent years, as well as a deeper understanding of lung adenocarcinoma at the molecular level. One example of a new targeted therapy is epidermal growth factor receptor (EGFR) and KRAS targeted gene therapy (6,7). However, targeted gene therapy is mainly used when patients have special characteristics. EGFR mutations occur more frequently in female lung adenocarcinoma patients with a non-smoking history (8). HER2 mutations tend to occur in non-smoking males (9). In contrast, KRAS mutations occur during the early development of smoking-related lung adenocarcinoma (10). Based on these observations, there is a need to develop individualized treatment programs for patients with unique clinical characteristics. Lung adenocarcinoma is caused by a combination of genetic and environmental effects (11).

More recently, the incidence of lung adenocarcinoma has increased in smokers (12). Tobacco smoke contains a mixture of harmful compounds and carcinogens (13). Therefore, smoking plays an important role in the development of lung adenocarcinoma. Although the correlation between smoking and lung adenocarcinoma has been demonstrated in previous studies, a meta-analysis of the gene mutations in a large number of tissue samples that considers the smoking history in lung adenocarcinoma has not yet been conducted (14). This large scale analysis can reduce the differences caused by different research conditions and can integrate the results from previous studies to evaluate the issue from another point of view. The development of microarray methods for large scale analysis of gene expression makes it possible to perform a more comprehensive analysis for potential genes and molecular pathways associated with lung adenocarcinoma in smoking patients (15). DNA microarray analysis has been applied to investigate whole genomic expression profiles and physiological mechanisms in health and disease (16,17). Therefore, a high-throughput microarray experiment was designed to analyse the genetic expression patterns and identify potential genes to target for lung adenocarcinoma (18). Meta-analysis provides a powerful tool for analysing microarray experiments by combining data from multiple studies (19). Genes identified by meta-analysis tend to overlap with genes identified in other studies, suggesting increased reliability (20). In addition to providing a new perspective, this research topic will further the understanding of the relationship between smoking and lung adenocarcinoma.

The aim of this study was to identify possible candidate genes for personalized treatment for lung adenocarcinoma patients with a history of smoking to provide patients with better treatment options and ensure a good prognosis. Therefore, we conducted a meta-analysis using the same platform of gene expression profile data that associated smoking with lung adenocarcinoma tissue.

 Materials and methods <sec> <title>Selection of microarray datasets for meta-analysis

According to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines published in 2009, we performed a detailed and comprehensive search of microarray datasets in the Gene Expression Omnibus (GEO) database of the National Center for Biotechnology Information (NCBI) (http://www.ncbi.nlm.nih.gov/geo/).

 Meta-analysis data

To maintain objectivity, the data were simultaneously extracted by two independent reviewers from the original search. Any discrepancies that arose between the two reviewers were resolved by consultation with a third reviewer. The terms ‘lung neoplasms’ and ‘lung cancer’ were considered keywords during our search for this study. In addition, studies that reported non-human data were excluded in the selection process for microarray datasets. Finally, 583 datasets were obtained from searching the Gene Expression Omnibus (GEO) database. Datasets with >20,288 samples were elected for the study. We included a dataset in the meta-analysis if it contained i) all samples on the Affymetrix Human Genome U133 Plus 2.0 Array platform, ii) samples from lung adenocarcinoma tissue and iii) samples with valid smoking statuses. According to the criteria, the four datasets that were selected from the 288 datasets included 477 lung adenocarcinoma tissues with valid smoking statuses. Then, we downloaded the lung adenocarcinoma tissue files (CEL) of the four microarray datasets from the GEO database with accession numbers GSE12667, GSE31210, GSE40791, and GSE50081. The four datasets included 477 lung adenocarcinoma patients; 327 of which were smokers, and 150 were non-smokers; the smokers included former smokers, current smokers and ex-smokers.

 Meta-analysis of microarray datasets using the same platform

We conducted the meta-analysis of gene expression profiles of the selected four microarray datasets by using R statistical software (http://www.r-project.org/) with the same platform. Prior to the meta-analysis, we performed data normalization of the four datasets using R statistical software. Then, we processed the meta-analysis using the MAMA, mataMA, affyPLM and CLL packages in R statistical software according to the t-test and z-score methods. During the meta-analysis with R statistical software, a list of differentially expressed genes (DEGs) (upregulated or downregulated) were identified based on the P-values (where the threshold was <0.005) and z-scores (where the threshold was an absolute value >3).

 Enrichment analysis of the GO function and KEGG pathway

It is important to understand the biological implications of the identified DEGs in lung adenocarcinoma tissue. According to the meta-analysis results, the most significant 200 DEGs (100 upregulated and 100 downregulated) were selected for enrichment analysis. Then, we conducted the functional enrichment analysis of the gene ontology (GO) function and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway using the WEB-based GEne SeT AnaLysis Toolkit (http://bioinfo.vanderbilt.edu/webgestalt/login.php) under a significance threshold of P<0.05.

 PPI network analysis

To further understand and predict the biological activity of the identified DEGs that were based on the results of the GO function and KEGG pathway enrichment analyses, we conducted a protein-protein interaction (PPI) network using the Cytoscape software. Prior to this analysis, we imported the DEG-encoding proteins into a protein-protein interaction (PPI) network, which was downloaded from the Biological General Repository for Interaction Datasets (BioGRID, http://thebiogrid.org/).

 Results <sec> <title>Selection of microarray datasets related to lung adenocarcinoma for meta-analysis

From the microarray datasets retrieved from the GEO database of NCBI, we extracted 477 GEO lung adenocarcinoma samples that belonged to four microarray datasets, which met our criteria for meta-analysis (see Materials and methods, and Fig. 1). All four GEO series (GSEs) were microarray datasets that used only lung adenocarcinoma tissue with valid smoking statuses. The GEO Platform Files (GPLs) from the four datasets (GSE12667, GSE31210, GSE40791 and GSE50081) were obtained using the Affymetrix ‘Gene Chip’ (Table I).

 Identification of upregulated or downregulated DEGs through meta-analysis

We performed the meta-analysis of gene expression profiles according to t-test and z-score methods using MAMA, mataMA, affyPLM and CLL packages in R statistical software on the same platform. According to the P-value (where the threshold was <0.005) and z-score (where the threshold was an absolute value >3), we were able to identify a total of 2,932 DEGs, including 1,806 upregulated and 1,126 downregulated genes using Venny 2.0 (http://bioinfogp.cnb.csic.es/tools/venny/index.html). The 200 genes that showed maximum upregulation and downregulation are shown in Tables II and III, and the overlapping DEGs based on P-values and z-scores are shown in Fig. 2. A subset of the top 50 DEGs (25 upregulated and 25 downregulated) in the four microarray datasets were visualized with heat maps using the Mev software and are shown in Figs. 3–6.

 Enrichment analysis of the GO function and KEGG pathway for the top 100 upregulated and downregulated DEGs

We classified the 200 DEGs that were identified through meta-analysis according to the GO hierarchy into functional categories (biological process, molecular function, and cellular component) and based on the KEGG pathway, with a significance threshold of <0.05. The most significant GO terms under the biological processes category were enriched in the following descending order: ‘cell cycle phase’ (GO:0022403), ‘M phase of mitotic cell cycle’ (GO:0000087) and ‘mitotic cell cycle’ (GO:0000278). The most enriched GO terms under the molecular functions and cellular components categories were ‘protein binding’ (GO:0005515) and ‘nuclear part’ (GO:0044428). The most enriched KEGG pathway terms were (in descending order): ‘Cell cycle’ (kegg:04110), ‘Oocyte meiosis’ (kegg:04114) and ‘Ubiquitin mediated proteolysis’ (kegg:04120) (Tables IV and V).

 PPI network analysis of the DEGs

To understand the biological meaning of the 8 upregulated DEGs identified by the KEGG pathway under the cell cycle pathway at the protein level, we constructed a PPI network for the proteins encoded by the 8 DEGs with interactions that included 541 nodes and 671 edges as shown in Fig. 7.

 Discussion

In the present study, we showed that genes are differentially expressed in lung adenocarcinoma in smoking and non-smoking patients. Some genes that showed the highest expression levels were found in lung adenocarcinoma patients who had a smoking history. Smoking consistently plays an important role in the development of lung adenocarcinoma. Cigarette smoke contains over 400 identified chemicals, at least 250 of which are implicated in tumour initiation and promotion (21). It is estimated that more than 50 chemicals in tobacco smoke cause cancers (22). Cigarette smoke is by far the most widespread link between exposure to known carcinogens and death from lung cancer (23). Lung adenocarcinoma is one of the main types of lung cancer in smokers and cannot be successfully treated with traditional treatments. Therefore, the effects of cigarette smoke on the genes that are implicated in lung adenocarcinoma are critical to increase our understanding of the carcinogenesis and in finding targeted genes. In our study, we found that the cell cycle pathway was significantly altered in lung adenocarcinoma tissues from patients with a smoking history.

Using several perspectives would allow us to characterise the underlying mechanisms of lung adenocarcinoma in smokers. Thus, we performed a meta-analysis of four independent microarray datasets using the same platform. The large number of DEGs identified in our study implies that our approach produces more reliable results in identifying differences in gene expression levels among lung adenocarcinoma patients who either had a smoking or a non-smoking history. In this study, the microarray expression datasets derived from lung adenocarcinoma tissue with patients with either a smoking or non-smoking history were publicly available. A number of previous studies have molecularly characterised the genetic profiles in lung cancer patients with or without a smoking history. The present investigation focused on a relatively larger cohort with 477 lung adenocarcinoma tissues from 327 smoking patients and 150 non-smoking patients, thereby providing a more powerful analysis. Our study results were highly consistent with previous DEG analyses, supporting the utility and validity of this analytical approach. Additionally, it also revealed that multiple biological processes and pathways, including cell cycle phase and the cell cycle pathway, were significantly affected in lung adenocarcinoma tissues from smoking patients compared to the non-smoking patients. Consistently, many previous studies have revealed that cigarette smoke extract accelerated premature gene mutations in the cell cycle pathway. Cigarette smoke extract alters the cell cycle via the phospholipid transfer protein/transforming growth factor-β1/cyclinD1/CDK4 pathway (24). Cigarette smoking is a major factor for many cancers including, pancreatic cancer, human ovarian cancer and colon cancer (25–27). This study identified the 8 overexpressed genes in the cell cycle pathway as CDC45, PLK1, CDC20, ANAPC7, CDC6, CHEK1, CCNE1 and ESPL1. According to the P-values in the meta-analysis, we identified a few significant DEGs including CDC45, CDC20, ANAPC7, CDC6, and ESPL1. Based on our meta-analysis results, these five genes may be potential target genes for the treatment of this disease.

CDC45 is a member of the highly conserved multiprotein complex including Cdc6/Cdc18. The replication factor CDC45 has essential functions in the initiation and plays an important role in the intra-S-phase checkpoint (28). CDC45 has been found to be upregulated in many neoplasms, such as breast neoplasms, colorectal neoplasms, lung neoplasms and haematological neoplasms (29).

CDC20 appears to act as a regulatory protein by interacting with several other proteins at multiple points in the cell cycle (30). The CDC20 gene might play an important role in the malignancy of NSCLC. Additionally, CDC20 has been found to be upregulated in lung cancer patients with a smoking history (31). In addition, through this analysis, we identified the overexpression of the CDC20 gene in lung adenocarcinoma patients who had a smoking history compared to the non-smoking patients. Combined with previous research, our analysis demonstrates that the CDC20 gene might play an important role in the treatment of lung adenocarcinoma in smoking patients.

ANAPC7 is an E3 ligase enzyme that ubiquinates various proteins involved in the cell cycle (32). This protein complex may have a pivotal role in the cell cycle control affecting pathological conditions such as cancer (33). ANAPC mutations have been reported in lung squamous cell carcinoma and small cell lung carcinoma.

CDC6, a cell cycle regulatory gene, is an essential regulator of DNA replication and plays important roles in the activation and maintenance of the checkpoint mechanism in the cell cycle (34). CDC6 has been associated with the oncogenic activities in human cancers, such as ovarian cancer, lung cancer and prostate cancer (35,36). However, the biological function and clinical significance of CDC6 in lung adenocarcinoma remain unclear. A previous study suggests that CDC6 is associated with the decline in lung function of ex-smoking in COPD (37). Our study also revealed CDC6 overexpression in lung adenocarcinoma patients with a smoking history compared to non-smoking patients.

ESPL1 is a protein-coding gene, and its overexpression has been found in a variety of human cancers such as rectum adenocarcinoma, prostate carcinoma, breast carcinoma and lung carcinoma (38,39). Consistent with earlier results, our study revealed that ESPL is overexpressed in lung adenocarcinoma in patients with a smoking history compared to those who had a non-smoking history.

Overall, the present study identified that a few genes are differentially expressed in lung adenocarcinoma samples between smoker and non-smoker patients. This observation supports previous studies; however, our analysis provides new insights that enable better understanding of the molecular mechanisms of lung adenocarcinoma in smokers, which may provide potential targets for the therapeutic design of individualized treatments for lung adenocarcinoma patients who have a smoking history.

 Acknowledgements

This research was supported in part by grants form the National Natural Science Foundation of China (31560314 to Q.L.) and the Natural Science Foundation of Jiangxi Province (2016BAB204168 to Q.L.).

 References KalemkerianGPAkerleyWBognerPBorghaeiHChowLQDowneyRJGandhiLGantiAKGovindanRGreculaJCNational Comprehensive Cancer NetworkSmall cell lung cancerJ Natl Compr Canc Netw117898201310.6004/jnccn.2013.0012233079843715060 PascheBGrantSCNon-small cell lung cancer and precision medicine: A model for the incorporation of genomic features into clinical trial designJAMA31119751976201410.1001/jama.2014.374224846033 SaitoMShiraishiKKunitohHTakenoshitaSYokotaJKohnoTGene aberrations for precision medicine against lung adenocarcinomaCancer Sci107713720201610.1111/cas.12941270276654968599 DingLGetzGWheelerDAMardisERMcLellanMDCibulskisKSougnezCGreulichHMuznyDMMorganMBSomatic mutations affect key pathways in lung adenocarcinomaNature45510691075200810.1038/nature07423189489472694412 WeirBAWooMSGetzGPernerSDingLBeroukhimRLinWMProvinceMAKrajaAJohnsonLACharacterizing the cancer genome in lung adenocarcinomaNature450893898200710.1038/nature06358179824422538683 de MelloRAMadureiraPCarvalhoLSAraújoAO'BrienMPopatSEGFR and KRAS mutations, and ALK fusions: Current developments and personalized therapies for patients with advanced non-small-cell lung cancerPharmacogenomics1417651777201310.2217/pgs.13.17724192124 PaulDRafaelOCConcurrent targetable genetic driver alterations in KRAS-mutant lung adenocarcinomaEur J Cancer60e15e16201610.1016/j.ejca.2016.03.055 NieQYangXNAnSJZhangXCYangJJZhongWZLiaoRQChenZHSuJXieZCYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA)n polymorphismEur J Cancer4719621970201110.1016/j.ejca.2011.04.01821616658 GowCHChangHTLimCKLiuCYChenJSShihJYComparable clinical outcomes in patients with HER2-mutant and EGFR-mutant lung adenocarcinomasGenes Chromosomes Cancer56373381201710.1002/gcc.2244228063177 RaponiMWinklerHDracopoliNCKRAS mutations predict response to EGFR inhibitorsCurr Opin Pharmacol8413418200810.1016/j.coph.2008.06.00618619559 WuCZhuJZhangXNetwork-based differential gene expression analysis suggests cell cycle related genes regulated by E2F1 underlie the molecular difference between smoker and non-smoker lung adenocarcinomaBMC Bioinformatics14365201310.1186/1471-2105-14-365243414323878503 AndreevKTrufaIDSiegemundRRiekerRHartmannASchmidtJSirbuHFinottoSImpaired T-bet-pSTAT1α and perforin-mediated immune responses in the tumoral region of lung adenocarcinomaBr J Cancer113902913201510.1038/bjc.2015.255263484464578079 TalhoutRSchulzTFlorekEvan BenthemJWesterPOpperhuizenAHazardous compounds in tobacco smokeInt J Environ Res Public Health8613628201110.3390/ijerph8020613215562073084482 LiYXiaoXJiXLiuBAmosCIRNA-seq analysis of lung adenocarcinomas reveals different gene expression profiles between smoking and nonsmoking patientsTumour Biol3689939003201510.1007/s13277-015-3576-y260816164674426 CheeMYangRHubbellEBernoAHuangXCSternDWinklerJLockhartDJMorrisMSFodorSPAccessing genetic information with high-density DNA arraysScience274610614199610.1126/science.274.5287.6108849452 SpiesMDasuMRSvrakicNNesicOBarrowREPerez-PoloJRHerndonDNGene expression analysis in burn wounds of ratsAm J Physiol Regul Integr Comp Physiol283R918R930200210.1152/ajpregu.00170.200212228062 GuoQMDNA microarray and cancerCurr Opin Oncol153643200310.1097/00001622-200301000-0000512490759 LiRWangHBekeleBNYinZCarawayNPKatzRLStassSAJiangFIdentification of putative oncogenes in lung adenocarcinoma by a comprehensive functional genomic approachOncogene2526282635200610.1038/sj.onc.120928916369491 YasrebiHComparative study of joint analysis of microarray gene expression data in survival prediction and risk assessment of breast cancer patientsBrief Bioinform17771785201610.1093/bib/bbv09226504096 HongFBreitlingRMcEnteeCWWittnerBSNemhauserJLChoryJRankProd: A bioconductor package for detecting differentially expressed genes in meta-analysisBioinformatics2228252827200610.1093/bioinformatics/btl47616982708 HechtSSTobacco carcinogens, their biomarkers and tobacco-induced cancerNat Rev Cancer3733744200310.1038/nrc119014570033 Brüske-HohlfeldIEnvironmental and occupational risk factors for lung cancerMethods Mol Biol472323200910.1007/978-1-60327-492-0_119107427 TaioliEGene-environment interaction in tobacco-related cancersCarcinogenesis2914671474200810.1093/carcin/bgn062185505732733188 ChaiXMLiYLChenHGuoSLShuiLLChenYJCigarette smoke extract alters the cell cycle via the phospholipid transfer protein/transforming growth factor-β1/CyclinD1/CDK4 pathwayEur J Pharmacol7868593201610.1016/j.ejphar.2016.05.03727260126 GlauertHPElliottRSHanSGAtheyMLeeEYGairolaCGEffect of cigarette smoke exposure and mutant Kras overexpression on pancreatic cell proliferationOncol Lett1319391943201710.3892/ol.2017.5606284543475403691 JeonSYGoREHeoJRKimCWHwangKAChoiKCEffects of cigarette smoke extracts on the progression and metastasis of human ovarian cancer cells via regulating epithelial-mesenchymal transitionReprod Toxicol65110201610.1016/j.reprotox.2016.06.01227327412 SchmidtUWollmannYFrankeCGrosseFSaluzHPHänelFCharacterization of the interaction between the human DNA topoisomerase IIbeta-binding protein 1 (TopBP1) and the cell division cycle 45 (Cdc45) proteinBiochem J409169177200810.1042/BJ2007087217887956 TerceroJALongheseMPDiffleyJFXA central role for DNA replication forks in checkpoint activation and responseMol Cell1113231336200310.1016/S1097-2765(03)00169-212769855 BroderickRRaineyMDSantocanaleCNasheuerHPCell cycle-dependent formation of Cdc45-Claspin complexes in human cells is compromized by UV-mediated DNA damageFEBS J28048884902201310.1111/febs.1246523910567 WeinsteinJCell cycle-regulated expression, phosphorylation, and degradation of p55Cdc. A mammalian homolog of CDC20/Fizzy/slp1J Biol Chem2722850128511199710.1074/jbc.272.45.285019353311 PollokSBauerschmidtCSängerJNasheuerHPGrosseFHuman Cdc45 is a proliferation-associated antigenFEBS J27436693684200710.1111/j.1742-4658.2007.05900.x17608804 RahimiHAhmadzadehAYousef-amoli SKokabeeLShokrgozarMAMahdianRKarimipoorMThe expression pattern of APC2 and APC7 in various cancer cell lines and AML patientsAdv Med Sci60259263201510.1016/j.advms.2015.04.00726046517 ZhangXXiaoTChengSTongTGaoYCigarette smoke suppresses the ubiquitin-dependent degradation of OLC1Biochem Biophys Res Commun407753757201110.1016/j.bbrc.2011.03.09521439932 BorladoLRMéndezJCDC6: From DNA replication to cell cycle checkpoints and oncogenesisCarcinogenesis29237243200810.1093/carcin/bgm26818048387 SunT-YXieH-JLiZHeHKongL-FExpression of CDC6 in ovarian cancer and its effect on proliferation of ovarian cancer cellsInt J Clin Exp Med910544105502016 YunSJKimYHKangHWKimWTKimYJLeeSCKimW-JKimTCDC6 mRNA expression is associated with the aggressiveness of prostate cancerEur Urol Suppl15e1625201610.1016/S1569-9056(16)30425-0 TakabatakeNToriyamaSIgarashiATokairinYTakeishiYKontaTInoueSAbeSShibataYKubotaIA novel polymorphism in CDC6 is associated with the decline in lung function of ex-smokers in COPDBiochem Biophys Res Commun381554559200910.1016/j.bbrc.2009.02.08019233139 FinettiPGuilleAAdelaideJBirnbaumDChaffanetMBertucciFESPL1 is a candidate oncogene of luminal B breast cancersBreast Cancer Res Treat1475159201410.1007/s10549-014-3070-z25086634 ZhangNPatiDBiology and insights into the role of cohesin protease separase in human malignanciesBiol Rev Camb Philos Soc9220702083201710.1111/brv.1232128177203

Selection process of the microarray datasets for meta-analysis of lung adenocarcinoma tissue with smoking status.

The 2932 overlapping differentially expressed genes (DEGs) based on P-value (where the threshold was <0.005) and z-score (where the threshold was an absolute value >3) were detected using Venny 2.1.0.

Heat-map representation of the expression profiles for the top 25 upregulated and downregulated genes in the GSE12667 dataset. The clustering of the selected genes on the heat-map was performed by using a hierarchical clustering algorithm that uses an average linkage method and Pearson's correlation coefficient.

Heat-map representation of the expression profiles for the top 25 upregulated and downregulated differentially expressed genes (DEGs) in the GSE131210 dataset. The clustering of the selected genes on the heat-map was performed using a hierarchical clustering algorithm that uses an average linkage method and Pearson's correlation coefficient.

Heat-map representation of the expression profiles for the top 25 upregulated and downregulated differentially expressed genes (DEGs) in the GSE40791 dataset. The clustering of the selected genes on the heat-map was performed using a hierarchical clustering algorithm that uses an average linkage method and Pearson's correlation coefficient.

Heat-map representation of the expression profiles for the top 25 upregulated and downregulated differentially expressed genes (DEGs) in the GSE50081 dataset. The clustering of the selected genes on the heat-map was performed using a hierarchical clustering algorithm that uses an average linkage method and Pearson's correlation coefficient.

Protein-protein interaction (PPI) network of the 8 upregulated differentially expressed genes (DEGs).

Characteristic of individual studies retrieved from Gene Expression Omnibus for meta-analysis.

Sample
Dataset Smoking status Non-smoking status Tissue Platform
GSE12667   40     8 Lung adenocarcinoma Affymetrix Human Genome U133 Plus 2.0 Array
GSE31210 111 115 Lung adenocarcinoma Affymetrix Human Genome U133 Plus 2.0 Array
GSE40791   82     4 Lung adenocarcinoma Affymetrix Human Genome U133 Plus 2.0 Array
GSE50081   94   23 Lung adenocarcinoma Affymetrix Human Genome U133 Plus 2.0 Array

The 100 upregulated genes.

Probe ID Gene P-value z-score
218670_at PUS1 1.26565E-14 −3.364765896
202856_s_at SLC16A3 1.31006E-14 −3.005755138
1553984_s_at DTYMK 2.73115E-14 −3.77721059
210052_s_at TPX2 3.28626E-14 −3.156028484
225620_at RAB35 6.72795E-14 −3.977400883
201710_at MYBL2 1.13465E-13 −3.753904206
200896_x_at HDGF 1.32117E-13 −6.606272774
233986_s_at PLEKHG2 1.34559E-13 −4.721664344
209186_at ATP2A2 1.52767E-13 −3.331133151
202954_at UBE2C 1.96732E-13 −3.433957425
234992_x_at ECT2 2.22933E-13 −3.540186205
218468_s_at GREM1 2.91323E-13 −3.421989473
221591_s_at FAM64A 3.1064E-13 −3.645233189
223308_s_at WDR5 3.71925E-13 −3.441383479
204092_s_at AURKA 4.20552E-13 −4.669115008
218593_at RBM28 5.6688E-13 −3.725504934
204962_s_at SLC35F6 6.05294E-13 −3.16224673
218726_at HJURP 9.13047E-13 −3.516355847
206364_at KIF14 1.22724E-12 −3.097688744
202870_s_at CDC20 1.31761E-12 −3.025537109
212680_x_at PPP1R14B 1.41753E-12 −3.30292041
220651_s_at MCM10 1.66711E-12 −3.962832885
222441_x_at SLMO2 1.88827E-12 −3.580783528
212541_at FLAD1 2.68452E-12 −4.335857984
223931_s_at CHFR 2.91989E-12 −5.133807637
203612_at BYSL 2.94276E-12 −3.332540528
219874_at SLC12A8 3.14992E-12 −4.228880162
229538_s_at IQGAP3 3.39373E-12 −4.67663851
38158_at ESPL1 3.52074E-12 −4.330276826
224753_at CDCA5 3.8165E-12 −3.102794749
200044_at SRSF9 5.19895E-12 −4.335016805
234915_s_at DENR 6.64646E-12 −3.045464333
206316_s_at KNTC1 7.17115E-12 −3.034017863
225468_at PATL1 7.18048E-12 −4.555045317
200756_x_at CALU 7.89546E-12 −3.573314992
202095_s_at BIRC5 8.23586E-12 −3.071731969
209464_at AURKB 8.59246E-12 −5.290213575
204430_s_at SLC2A5 9.54348E-12 −3.999406252
219918_s_at ASPM 9.98956E-12 −3.385882475
218512_at WDR12 1.10383E-11 −3.127647757
203702_s_at TTLL4 1.10745E-11 −3.222581427
242944_at FAM83A 1.14144E-11 −6.56980268
206205_at MPHOSPH9 1.17426E-11 −3.286743793
221520_s_at CDCA8 1.222E-11 −3.189226567
220011_at AUNIP 1.32323E-11 −5.645650742
203004_s_at MEF2D 1.41975E-11 −6.628593875
204005_s_at PAWR 1.44695E-11 −4.589047842
200744_s_at GNB1 1.57292E-11 −3.309783419
202580_x_at FOXM1 1.92268E-11 −3.156340828
201761_at MTHFD2 2.141E-11 −3.158744955
204603_at EXO1 2.21381E-11 −3.093222948
225401_at C1orf85 2.37168E-11 −4.583223012
228703_at P4HA3 2.44789E-11 −4.354770166
204709_s_at KIF23 2.78617E-11 −3.130038648
212322_at SGPL1 3.15128E-11 −3.303129755
202779_s_at UBE2S 3.25431E-11 −3.246262139
210386_s_at MTX1 3.28946E-11 −3.499628552
205733_at BLM 3.44063E-11 −3.183717987
223307_at CDCA3 3.49276E-11 −3.223011207
1555943_at PGAM5 3.49287E-11 −4.908658645
219493_at SHCBP1 3.69571E-11 −3.171551777
223785_at FANCI 4.13012E-11 −3.72118368
212021_s_at MKI67 4.16123E-11 −3.291213712
200750_s_at RAN 4.22222E-11 −3.060882727
229892_at EP400NL 4.39129E-11 −4.569469931
204126_s_at CDC45 4.39451E-11 −3.107729352
226949_at GOLGA3 4.51967E-11 −3.569550938
205895_s_at NOLC1 4.80713E-11 −3.479055682
205691_at SYNGR3 4.92397E-11 −6.345274404
204641_at NEK2 4.94367E-11 −3.260850411
223365_at DHX37 5.08806E-11 −6.413792983
229610_at CKAP2L 5.22091E-11 −3.506800101
207590_s_at CENPI 5.60811E-11 −3.706888048
224742_at ABHD12 6.35478E-11 −3.351775356
209052_s_at WHSC1 6.63429E-11 −3.610265902
206074_s_at HMGA1 6.86768E-11 −3.035687751
225554_s_at ANAPC7 7.7532E-11 −4.210797517
204649_at TROAP 8.73972E-11 −3.344919358
212871_at MAPKAPK5 9.64493E-11 −6.062517519
201954_at ARPC1B 1.04984E-10 −3.29272791
203967_at CDC6 1.15562E-10 −3.032999971
205024_s_at RAD51 1.27276E-10 −3.317013997
201127_s_at ACLY 1.40898E-10 −3.598775099
201292_at TOP2A 1.69439E-10 −3.586121076
1555274_a_at EPT1 1.82091E-10 −3.107139925
222077_s_at RACGAP1 1.98689E-10 −3.463568797
212949_at NCAPH 2.04934E-10 −3.123094613
214866_at PLAUR 2.8521E-10 −6.066208054
209836_x_at BOLA2B 3.03036E-10 −3.581736948
236957_at CDCA2 3.37438E-10 −3.267349523
204318_s_at GTSE1 3.6192E-10 −3.165321627
222622_at PGP 3.89473E-10 −3.166188967
218497_s_at RNASEH1 4.25561E-10 −3.276072648
218984_at PUS7 4.45897E-10 −4.331098443
205394_at CHEK1 4.6472E-10 −3.071160119
210821_x_at CENPA 4.95303E-10 −3.345790152
223484_at C15orf48 6.08452E-10 −3.301630777
213523_at CCNE1 6.55394E-10 −4.360746545
209642_at BUB1 7.26076E-10 −3.325492652
202240_at PLK1 8.52925E-10 −3.537560833

The 100 downregulated genes.

Probe ID Gene P-value z-score
225956_at CREBRF 0 3.056084
209740_s_at PNPLA4 0 8.750866
204754_at HLF 0 3.370263
230163_at GFRA1 0 3.162875
242496_at ART4 0 3.160279
221518_s_at USP47 0 4.047036
235830_at NT5DC1 0 3.951365
235155_at BDH2 0 3.138416
208741_at SAP18 0 3.588813
228692_at PREX2 0 3.033953
211999_at MIR4738 0 3.297597
227562_at LAMTOR3 0 3.340261
229573_at USP9X 2.22E-16 4.870675
205756_s_at F8 2.22E-16 3.20333
229319_at BC022047 2.22E-16 3.024973
228411_at PARD3B 4.44E-16 3.454669
212425_at SCAMP1 4.44E-16 3.064577
213876_x_at ZRSR2 4.44E-16 5.174619
239252_at COX7B 4.44E-16 3.999039
200933_x_at RPS4X 4.44E-16 5.299386
210829_s_at SSBP2 4.44E-16 3.082665
206767_at RBMS3 6.66E-16 3.71459
226709_at ROBO2 6.66E-16 3.615428
203991_s_at KDM6A 8.88E-16 5.796073
227274_at SYNJ2BP-COX16 1.11E-15 3.517758
228504_at SCN7A 1.78E-15 3.16819
225998_at GAB1 2E-15 3.00431
218346_s_at SESN1 2.44E-15 3.055691
224976_at NFIA 3.11E-15 3.007387
205857_at SLC18A2 4.22E-15 3.457499
225352_at SEC62 6.88E-15 3.26132
200810_s_at CIRBP 1.49E-14 3.072028
200983_x_at CD59 2.22E-14 3.24769
212249_at PIK3R1 2.44E-14 4.98666
241689_at METTL14 3.42E-14 3.311901
228716_at THRB 4.88E-14 3.021776
205259_at NR3C2 5E-14 3.392261
223588_at THAP2 5.44E-14 6.445672
201427_s_at SEPP1 6.02E-14 3.146142
219427_at FAT4 7.7E-14 3.056389
209807_s_at NFIX 7.97E-14 3.105386
201498_at USP7 8.55E-14 3.827248
228243_at RP11-5C23.1 8.84E-14 3.43588
238786_at ANK3 1.58E-13 3.075604
233249_at LOC100507073 1.61E-13 3.069721
208633_s_at MACF1 1.79E-13 3.260397
226816_s_at KIAA1143 1.94E-13 3.431996
208792_s_at CLU 2.46E-13 3.627978
210426_x_at RORA 2.51E-13 3.077789
229969_at SEC63 2.86E-13 3.019815
225811_at C11orf58 2.90212E-13 3.095344537
227847_at EPM2AIP1 3.27738E-13 3.460553723
201019_s_at EIF1AX 3.35065E-13 4.257274339
223695_s_at ARSD 3.475E-13 5.635180257
228905_at PCM1 3.53051E-13 3.340750721
217707_x_at SMARCA2 3.67262E-13 4.020194349
225093_at UTRN 6.21503E-13 3.138806562
227425_at REPS2 7.33413E-13 3.055352168
211734_s_at FCER1A 8.45324E-13 3.411503985
244007_at ZNF462 9.36362E-13 3.786986943
212675_s_at CEP68 1.00742E-12 3.307657084
238454_at ZNF540 1.13221E-12 3.186059238
224889_at FOXO3 1.14175E-12 3.853408162
1558512_at RP11-819C21.1 1.37579E-12 3.144887286
213802_at PRSS12 1.47216E-12 4.357472705
225465_at MAGI1 1.47393E-12 4.208157151
223126_s_at C1orf21 1.56142E-12 3.186640389
230479_at EIF3F 1.58984E-12 3.299359045
228448_at MAP6 1.66223E-12 3.143593284
217779_s_at PNRC2 1.91847E-12 3.246325539
1560648_s_at TSPYL1 1.9309E-12 3.760805629
212936_at FAM172A 2.19358E-12 4.299840018
227091_at CCDC146 2.29194E-12 3.206298087
221564_at PRMT2 2.38565E-12 3.547995663
43427_at ACACB 2.44649E-12 3.004593504
229384_at CTC-429P9.3 2.57394E-12 3.228782722
222663_at RIOK2 2.69118E-12 3.35934368
238472_at FBXO9 2.69273E-12 3.562133246
222533_at CRBN 2.82396E-12 3.004216036
228751_at CLK4 3.30425E-12 3.359190366
208832_at ATXN10 3.36042E-12 3.408974266
238043_at ARID1B 3.38618E-12 3.280003422
1559412_at LINC00478 3.50475E-12 4.041998876
238081_at WDFY3-AS2 3.68106E-12 3.077236586
228760_at SRSF8 4.13358E-12 3.538832842
235240_at ATXN3 4.47198E-12 3.59474854
240806_at RPL15 5.22404E-12 3.229351616
228027_at GPRASP2 5.30198E-12 3.191435286
209815_at PTCH1 5.63194E-12 3.080285017
208760_at UBE2I 6.31295E-12 3.075043093
229317_at KPNA5 6.53722E-12 3.749106743
228420_at PDCD2 7.1736E-12 3.442288871
227520_at TXLNG 7.54685E-12 5.386988658
244294_at GTF2H5 7.70273E-12 4.035395557
204011_at SPRY2 7.75358E-12 3.811245705
209614_at ADH1B 7.83396E-12 3.188622844
226774_at FAM120B 8.43059E-12 3.286960689
235612_at PRPF38A 1.023E-11 3.636955078
232122_s_at VEPH1 1.20886E-11 3.052642894
216342_x_at RPS4XP2 1.22578E-11 6.967247025

The enrichment based on the top 10 GO functions shows the top 100 upregulated and downregulated DEGs.

GO ID GO term No. of Genes P-value
GO:0022403 Cell cycle phase   48 3.26E-18
GO:0000087 M phase of mitotic cell cycle   33 6.78E-18
GO:0022402 Cell cycle process   52 6.78E-18
GO:0000278 Mitotic cell cycle   45 6.78E-18
GO:0044428 Nuclear part   70 6.12E-10
GO:0031981 Nuclear lumen   64 1.48E-09
GO:0044422 Organelle part 112 1.63E-09
GO:0005515 Protein binding 112 1.27E-05
GO:0042975 Peroxisome proliferator activated receptor binding     3 0.0097
GO:0019899 Enzyme binding   25 0.0135

GO, gene ontology; DEGs, differentially expressed genes.

The enrichment based on the top KEGG pathway shows the top 100 upregulated and downregulated DEGs.

KEGG ID KEGG pathway No. of Genes P-value
kegg:04110 Cell cycle 8 2.45E-06
kegg:04114 Oocyte meiosis 7 9.76E-06
kegg:04120 Ubiquitin mediated proteolysis 5 0.0032
kegg:03013 RNA transport 5 0.0036
kegg:04610 Complement and coagulation cascades 3 0.013
kegg:04115 p53 signalling pathway 3 0.013
kegg:05200 Pathways in cancer 6 0.013
kegg:03060 Protein export 2 0.0144
kegg:03008 Ribosome biogenesis in eukaryotes 3 0.0152
kegg:03440 Homologous recombination 2 0.0168

KEGG, Kyoto Encyclopedia of Genes and Genomes; DEGs, differentially expressed genes.